Literature DB >> 19663672

Influence of the VEGF-A 936C>T germinal polymorphism on tumoral VEGF expression in head and neck cancer.

Jean-Louis Formento1, Marie-Christine Etienne-Grimaldi, Mireille Francoual, Gilles Pagès, Cercina Onesto, Patricia Formento, Emmanuel Chamorey, Olivier Dassonville, Gilles Poissonnet, Gérard Milano.   

Abstract

AIMS: Elevated tumoral vascular endothelial growth factor A (VEGF-A) expression is linked to poor survival in head and neck cancer patients. The aim of the present study was to analyze the influence of VEGF-A gene polymorphisms on tumoral VEGF-A expression and to test their prognostic value in head and neck cancer patients. MATERIALS &
METHODS: VEGF-A polymorphisms at position -2578C>A, -1498T>C, -1154G>A, -634G>C and 936C>T were analyzed (PCR-RFLP) in tumoral DNA, along with tumoral VEGF-A expression (ELISA), in 49 Caucasian head and neck cancer patients.
RESULTS: A trend towards a difference in tumoral VEGF-A expression depending on 936C>T polymorphism was observed, with a median at 540 pg/mg prot in CT + TT patients (n = 5) versus 940 pg/mg prot in CC patients (n = 44) (p = 0.064). VEGF-A expression was not related to any other polymorphism. Unlike tumoral VEGF-A expression, the analyzed genotypes were not related to patient survival.
CONCLUSION: As opposed to tumoral VEGF-A expression, VEGF-A gene polymorphisms are not of prognostic value in head and neck cancer patients. Further studies aimed at confirming the influence of VEGF-A 936C>T germinal polymorphism on tumoral VEGF-A expression are needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19663672     DOI: 10.2217/pgs.09.54

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  7 in total

1.  Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.

Authors:  Marie-Christine Etienne-Grimaldi; Patricia Formento; Armelle Degeorges; Jean-Yves Pierga; Rémi Delva; Xavier Pivot; Florence Dalenc; Marc Espié; Corinne Veyret; Jean-Louis Formento; Mireille Francoual; Magali Piutti; Patricia de Crémoux; Gérard Milano
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

2.  Vascular endothelial growth factor A gene (VEGFA) polymorphisms and expression of VEGFA gene in lung cancer patients of Kashmir Valley (India).

Authors:  Niyaz A Naik; Imtiyaz A Bhat; Dil Afroze; Roohi Rasool; Hyder Mir; Syed Irtiza Andrabi; Sonaullah Shah; Mushtaq A Siddiqi; Zafar A Shah
Journal:  Tumour Biol       Date:  2012-01-10

3.  Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.

Authors:  Xiaoxiang Guan; Ming Yin; Qingyi Wei; Hui Zhao; Zhensheng Liu; Li-E Wang; Xianglin Yuan; Michael S O'Reilly; Ritsuko Komaki; Zhongxing Liao
Journal:  BMC Cancer       Date:  2010-08-16       Impact factor: 4.430

4.  Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients.

Authors:  Mario Scartozzi; Cristian Loretelli; Eva Galizia; Alessandra Mandolesi; Mirco Pistelli; Alessandro Bittoni; Riccardo Giampieri; Luca Faloppi; Maristella Bianconi; Michela Del Prete; Francesca Bianchi; Laura Belvederesi; Italo Bearzi; Stefano Cascinu
Journal:  PLoS One       Date:  2012-07-09       Impact factor: 3.240

5.  Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.

Authors:  Sophie Piperno-Neumann; Alhassane Diallo; Marie-Christine Etienne-Grimaldi; François-Clément Bidard; Manuel Rodrigues; Corine Plancher; Pascale Mariani; Nathalie Cassoux; Didier Decaudin; Bernard Asselain; Vincent Servois
Journal:  Oncologist       Date:  2016-02-24

6.  Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.

Authors:  Maristella Bianconi; Luca Faloppi; Cristian Loretelli; Antonio Zizzi; Riccardo Giampieri; Alessandro Bittoni; Kalliopi Andrikou; Michela Del Prete; Luciano Burattini; Rodolfo Montironi; Mario Scartozzi; Stefano Cascinu
Journal:  Oncotarget       Date:  2016-06-21

7.  VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.

Authors:  M Scartozzi; M Bianconi; L Faloppi; C Loretelli; A Bittoni; M Del Prete; R Giampieri; E Maccaroni; S Nicoletti; L Burattini; D Minardi; G Muzzonigro; R Montironi; S Cascinu
Journal:  Br J Cancer       Date:  2012-11-29       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.